Objective: This prospective study evaluated systolic and diastolic cardiac functions in pediatric cirrhosis using conventional and tissue Doppler imaging (TDI), and explored their correlation with liver severity scores. Methods: Conducted at Inonu University, we enrolled 75 pediatric cirrhotic patients (44 compensated, 31 decompensated) from Pediatric Gastroenterology and 61 controls of similar age and sex without structural/functional heart disease from Pediatric Cardiology outpatients. All underwent clinical, laboratory, and echocardiographic assessments. To address multiple testing, Bonferroni correction was applied. Adjustments for age, sex, and disease severity were integrated into the correlation matrices to control for confounding parameters. Results: The cirrhosis cohort exhibited significantly higher heart rates, ejection fractions, and aortic/pulmonary velocity-time integrals than controls (p < 0.05). Conversely, growth-independent diastolic indices revealed distinct relaxation impairment: transmitral E/A and annular e′/a′ ratios were significantly lower, while Mitral E/e′ was elevated (p < 0.05). Deceleration time, isovolumetric relaxation time, and Myocardial Performance Index (MPI) were significantly prolonged (p < 0.01). Decompensated patients demonstrated significantly higher left ventricular filling pressures (Mitral E/e′) than compensated patients and controls (p = 0.002). After adjusting for age and sex, the Pediatric End-Stage Liver Disease (PELD) score maintained significant positive correlations with heart rate (r = 0.408) and Mitral E/e′ (r = 0.433) (p ≤ 0.002). FIB-4 and APRI scores showed positive correlations with VTI and TAPSE, markers of right ventricular volume overload (p < 0.05). Conclusions: Hyperdynamic circulation appears to mask resting systolic metrics in pediatric cirrhosis. However, prolonged diastolic phases and increased MPI suggest presence of subclinical myocardial dysfunction, especially during clinical decompensation. Routine non-invasive liver staging scores show potential clinical utility as ancillary screening tools for early cardiovascular risk evaluation.
This study examined the clinical, genetic, and treatment response characteristics of pediatric patients with acute myeloid leukemia (AML) treated according to the 2004 and 2012 AML-BFM protocols. This study aimed to determine survival outcomes and the factors affecting them, and to compare the results with international data. This study retrospectively evaluated pediatric AML patients aged < 18 years in eastern Turkey between January 2010 and December 2023. The AML-BFM 2004 and AML-BFM 2012 protocols were applied to the patients. The risk groups of the patients were determined based on their responses to chemotherapy and genetic results. Survival analyses were conducted using the Kaplan–Meier method. Univariate and multivariate Cox regression analyses were used. Forty-nine patients were included in this study. The median age at diagnosis was 12 years, and 51% of the patients were female. The most common morphological subtype was AML M3, accounting for 32.7% of cases. Complete remission was achieved in 81.6% of patients after induction therapy, whereas 12.2% died during this phase. Relapse occurred in 26.5% of patients. Overall, 38.8% of patients died. AML-M3 patients had a median overall survival (OS) of 113 months, which was better than that of non-AML-M3 patients. Five-year survival rates were 94% for AML-M3 patients and 43% for non-AML-M3 patients. Lower survival rates were observed in patients with leukocyte counts ≥ 50 × 10⁹/L, low hemoglobin levels, non-AML-M3, and poor induction response. Mortality was higher in patients younger than two years and > 14 years. There were no significant differences in mortality, survival, or relapse rates between the AML-BFM 2004 and AML-BFM 2012 protocols ( p > 0.005). No significant association was observed between mortality and leukapheresis. Further research should focus on developing personalized treatments for high-risk patients and those without non-AML-M3, given their poorer survival rates than those of AML-M3 patients.
Objective: This study aimed to investigate blood lead levels (BLLs) in children with microcytic anemia living in Malatya and its surrounding areas, to compare them with those of healthy children, and to evaluate the relationship between BLLs, microcytic anemia, and possible risk factors for lead exposure. Materials and Methods: This study included 220 children aged 2-17 years between December 2018 and June 2019. Of these, 110 had microcytic anemia and 110 were healthy controls. BLLs were measured in all participants. A questionnaire was administered to assess potential risk factors for lead exposure, including plastic toy exposure, residence near a main road, parental or household occupational/hobby-related lead exposure, residence in a house built before 1950, and immigrant or refugee status. Results: The median age of the participants was 8.0 years (interquartile range: 3.5-13.0). The mean BLL was 7.6±0.3 µg/dL, and all participants had BLLs above 5 µg/dL. All children had plastic toy exposure, and none lived in a house built before 1950. There was no significant difference in BLLs between children with microcytic anemia and healthy controls. BLLs were significantly higher in children whose parents or household members had occupational or hobby-related lead exposure than in those without such exposure (p<0.001). BLLs were also significantly higher in immigrant or refugee children than in non-immigrant and non-refugee children (p<0.001). Conclusion: Children living in Malatya and its surrounding areas had BLLs above current reference values; however, BLLs were not associated with microcytic anemia. Higher BLLs among immigrant and refugee children and in children with household occupational or hobby-related exposure indicate the need for targeted screening and environmental source control. Preventing lead exposure is important to reduce long-term adverse health effects in children.
Children with Down syndrome (DS) have a 150-times increased risk of myeloid leukemia (ML). In DS patients, in addition to DS-ML, common acute myeloid leukemia (AML) subtypes (standard-AML), observed in patients without DS, may also be seen. We evaluated ML types developing among DS cases, along with clinical features, survival, relapse, and mortality rates. The study included DS children aged 6 months to 18 years with newly diagnosed ML. Patients were classified retrospectively into two groups according to WHO guidelines and BFM-AML protocol recommendations as DS-ML and standard AML-DS. Among 53 DS patients, 71.7% (n = 38) had DS-ML and 28.3% (n = 15) had standard AML-DS. The mean age in the DS-ML group was significantly lower than the standard AML-DS group (23 ± 9 vs. 48 ± 51 months, p = 0.033). The 5-year overall survival (OS) and event-free survival (EFS) in the DS-ML group were 84.1%±6.0% and 81.3%±6.4%, respectively. For the standard AML, OS and EFS were 53.3%±12.9% and 45.7%±13.1%, respectively. The DS-ML group had significantly higher OS and EFS than the standard AML-DS group (p = 0.039 and p = 0.025, respectively). In our study, DS-ML and standard AML-DS were evaluated separately, which significantly contributes to the literature on the clinical and laboratory features of both groups, given the limited data on these topics. In the DS-ML group, complete remission, OS, and EFS were significantly higher than in the standard AML-DS. Differentiating DS-ML from standard AML-DS will ensure that patients with these biologically distinct diseases receive treatment of appropriate intensity and increase survival by reducing early mortality and relapse risk.